Hyperuricemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

June 2022 | 93 pages | ID: HC13535A67D5EN
Global Markets Direct

Abstracts

Hyperuricemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperuricemia – Drugs In Development, 2022, provides an overview of the Hyperuricemia (Metabolic Disorders) pipeline landscape.

High uric acid level, or hyperuricemia, is an excess of uric acid in blood. Symptoms include joints become swollen, tender and red, fever, chills, fatigue and kidney problems (caused by formation of kidney stones), or problems with urination. Predisposing factors include age, family history and certain medications. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroid medications.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hyperuricemia – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hyperuricemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hyperuricemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperuricemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 11, 7, 4, 7 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.

Hyperuricemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperuricemia (Metabolic Disorders).
• The pipeline guide reviews pipeline therapeutics for Hyperuricemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Hyperuricemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Hyperuricemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Hyperuricemia (Metabolic Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Hyperuricemia (Metabolic Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Hyperuricemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Hyperuricemia – Overview
Hyperuricemia – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hyperuricemia – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hyperuricemia – Companies Involved in Therapeutics Development
Hyperuricemia – Drug Profiles
Hyperuricemia – Dormant Projects
Hyperuricemia – Discontinued Products
Hyperuricemia – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Hyperuricemia, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Hyperuricemia – Pipeline by Allena Pharmaceuticals Inc, 2022
Hyperuricemia – Pipeline by Amendment Biomedical (Hangzhou) Research Institute Co Ltd, 2022
Hyperuricemia – Pipeline by Arthrosi Therapeutics Inc, 2022
Hyperuricemia – Pipeline by AstraZeneca Plc, 2022
Hyperuricemia – Pipeline by Evopoint Bioscience Co Ltd, 2022
Hyperuricemia – Pipeline by Fochon Pharmaceutical Ltd, 2022
Hyperuricemia – Pipeline by FortuneRock (China) Ltd, 2022
Hyperuricemia – Pipeline by Fuji Yakuhin Co Ltd, 2022
Hyperuricemia – Pipeline by Guangdong East Sunshine Pharmaceutical Co Ltd, 2022
Hyperuricemia – Pipeline by Hangzhou Grand Biologic Pharmaceutical Inc, 2022
Hyperuricemia – Pipeline by Hinova Pharmaceuticals Co Ltd, 2022
Hyperuricemia – Pipeline by InventisBio Inc, 2022
Hyperuricemia – Pipeline by J-Pharma Co Ltd, 2022
Hyperuricemia – Pipeline by Jiangsu Atom Bioscience and Pharmaceutical Co Ltd, 2022
Hyperuricemia – Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Hyperuricemia – Pipeline by Nippon Chemiphar Co Ltd, 2022
Hyperuricemia – Pipeline by NuBioPharma LLC, 2022
Hyperuricemia – Pipeline by PegBio Co Ltd, 2022
Hyperuricemia – Pipeline by Shanghai Institute of Biological Products Co Ltd, 2022
Hyperuricemia – Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022
Hyperuricemia – Pipeline by Shanghai Yingli Pharmaceutical Co Ltd, 2022
Hyperuricemia – Pipeline by Shanton Pharma Co Ltd, 2022
Hyperuricemia – Pipeline by Stealth Biologics LLC, 2022
Hyperuricemia – Pipeline by Teijin Pharma Ltd, 2022
Hyperuricemia – Pipeline by Tonghua Dongbao Pharmaceutical Co Ltd, 2022
Hyperuricemia – Pipeline by Waterstone Pharmaceuticals (Wuhan) Ltd, 2022
Hyperuricemia – Dormant Projects, 2022
Hyperuricemia – Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Hyperuricemia, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022